Skip to content
Single Family OfficePuts its own capital into companiesActive · deal in last 18 monthsLAST VERIFIED Oct 2026 · 9 SOURCES

Tarsadia Investments

Also known as Tarsadia, The Tarsadia Group, LLC

Newport Beach family office investment platform of the Patel family (hotel origins) deploying permanent capital across venture/growth, life sciences, real estate, secondaries and public markets.

USEFUL FOR Founders · Business owners seeking a long-term partner · Co-investors

Tarsadia Investments is the private-markets platform of the Patel family's Tarsadia family office; Tarsadia Capital is its public-markets (global equities and commodities) platform, run from New York, and Tarsadia Enterprises is listed as a third division on its team page.

Family & background

FAMILY
Patel
WEALTH ORIGIN
Hospitality (hotel ownership and operation; Tarsadia began as a hospitality owner-operator under founder Tushar Patel)
HEADQUARTERS
Newport Beach, United States
OUTSIDE CAPITAL
No — own capital only

Investment approach

SECTORS
Biotech & Life SciencesFintechHealthTechReal Estate & PropTechConsumer & E-commerce
GEOGRAPHY
Global
STAGES
SeedGrowth
ROUTES
Companies (own capital)
STRATEGIES
Direct investmentsVenture capitalPrivate equityReal estatePublic equitiesPrivate credit
LATEST DEAL
ClinTrial Research (Growth equity) · Dec 2025
INBOUND
Accepts submissions

Overview

Tarsadia is a multi-generational family office investment platform headquartered in Newport Beach, California, with a second office in New York; it was founded about five decades ago as a hospitality operating company and reports 30+ years of direct investing. Its website states that it invests proprietary capital on behalf of its principals and related entities and does not provide investment advisory services to the public. Tarsadia Investments, its private-markets platform, runs four strategies: Alpha-T Direct (thesis-driven incubations, hybrid venture/growth and technology transformation), Life Sciences (biosimilars, clinical-stage therapeutics, drug delivery), Real Estate (hospitality acquisitions, development and asset management) and Strategic Opportunities (GP-led secondaries, LP liquidity events and structured capital, launched in September 2026); Tarsadia Capital invests in global equities and commodities and the portfolio page assigns it the Interharbour private trade-finance credit platform. The portfolio page lists 27 holdings including Nubank, Creditas, Bolttech, Kashiv Biosciences, Amneal Pharmaceuticals and ClinTrial Research.

Investment thesis

Permanent, patient capital without fund-life constraints, combined with an owner's mindset from its hospitality operating heritage, applied to high-conviction investments in companies it believes can define their categories; investment horizons are often a decade or more.

Holdings & investments (26)

People

  • Gregory Caplan
    Principal, Investment Team (Tarsadia Investments) · source
  • Kunal Gupta
    Vice President, Investment Team (Tarsadia Investments) · source
  • Jay Santoro
    Vice President, Investment Team (Tarsadia Investments) · source
  • Andrew Ritts
    Senior Associate, Investment Team (Tarsadia Investments) · source
  • Krishan Tarsadia
    Senior Associate, Investment Team (Tarsadia Investments) · source
  • Wendy Yan
    Senior Associate, Investment Team (Tarsadia Investments) · source
  • Wei Liu
    Risk Manager, Investment Team (Tarsadia Capital) · source
  • Aman Patel
    Associate, Investment Team (Tarsadia Capital) · source
  • Tushar Patel
    Chairman & Founder · source
  • Mitchell Caplan
    Chief Executive Officer · source
  • Ed Coss
    Executive Vice President & Chief Legal Officer · source
  • David Browne
    Chief Financial Officer · source
  • Rishi Reddy
    Managing Director, Head of Alpha-T Direct · source
  • Gautam Patel
    Managing Director, Head of Life Sciences · source
  • Vikram Patel
    Managing Director, Head of Tarsadia Capital · source
  • Viman Singh
    Principal, Head of Strategic Opportunities · source
  • Alkesh Patel
    Senior Vice President, Head of Real Estate · source
  • Gerard Forster
    Chief Technology Officer · source
  • Ankur Mulji
    Vice President, Real Estate · source
  • Michael Ching
    Managing Director, Head of Research & Liquid Strategies (Tarsadia Capital) · source
  • Shankar Raman
    Principal, Head of Commodities Trade Capital (Tarsadia Capital) · source
  • Sagar Desai
    Vice President, Commodities and Private Credit (Tarsadia Capital) · source
  • Andrew Yeung
    Chief Operating Officer, General Counsel (Tarsadia Capital) · source

Frequently asked questions

Tarsadia Investments is a single family office based in Newport Beach, the United States.

Tarsadia Investments invests on behalf of the Patel family (Hospitality (hotel ownership and operation; Tarsadia began as a hospitality owner-operator under founder Tushar Patel)).

Tarsadia Investments invests its own capital into companies. Its stated asset mix includes direct investments, venture capital, private equity, real estate, public equities and private credit.

Tarsadia Investments invests at Seed and Growth stages in Biotech & Life Sciences, Fintech, HealthTech, Real Estate & PropTech and Consumer & E-commerce.

Key people at Tarsadia Investments include Tushar Patel (Chairman & Founder), Mitchell Caplan (Chief Executive Officer), Ed Coss (Executive Vice President & Chief Legal Officer) and David Browne (Chief Financial Officer).

Tarsadia Investments's holdings and investments include ClinTrial Research, Kashiv Biosciences, Nubank, Amneal Pharmaceuticals, Asana Biosciences, AvantStay, Bolttech and ChronicleBio, among others.

The most recent publicly reported investment by Tarsadia Investments is ClinTrial Research (Growth equity), announced in Dec 2025.

Tarsadia Investments states that it accepts submissions through its official contact page.

No. Tarsadia Investments invests its own capital and does not raise money from outside investors.